Resistance Profile

STRIBILD resistance profile through 144 weeks in Studies 103 and 1021,2

701 subjects randomized to receive STRIBILD -> 35 were viremic and analyzed for resistance mutations - > 18 developed 1 or more resistance mutations

*Viremic subjects defined as having HIV-1 RNA >400 copies/mL at virologic failure, week 144, or time of study discontinuation. Viremic subjects who received at least 8 weeks of treatment and had evaluable genotypic data were included in this analysis.

Development of drug resistance in adults who had no antiretroviral treatment history (combined results of Studies 103 & 102)1-3

Most common drug resistance mutations (combined results from Studies 103 and 102)

  • The most common resistance-associated substitutions that emerged in subjects taking STRIBILD were:1
    • RT: M184V/I (n = 17), K65R (n = 5)
    • IN: E92Q (n = 9), N155H (n = 5), Q148R (n = 3), T66I (n = 2), and T97A (n =1)a
  • All subjects with evaluable data for RT and IN and who developed integrase substitutions associated with EVG resistance (n = 14) also developed the M184V/I RT substitutions, conferring reduced susceptibility to both EVG and FTC

aIn isolates with primary EVG resistance substitutions, additional substitutions in integrase associated with resistance to EVG were H51Y, L68I/V, G70R, I73V, G140C, S153A, E157Q, and G163R (pooled analysis).

Important Safety Information


  • Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate (tenofovir DF), a component of STRIBILD, in combination with other antiretrovirals.
  • STRIBILD is not approved for the treatment of chronic hepatitis B virus (HBV) infection and the safety and efficacy of STRIBILD have not been established in patients coinfected with HBV and HIV-1. Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HBV and HIV-1 and have discontinued emtricitabine or tenofovir DF, components of STRIBILD. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue STRIBILD. If appropriate, initiation of anti-hepatitis B therapy may be warranted.


STRIBILD is indicated as a complete regimen for the treatment of HIV-1 infection in adults who have no antiretroviral (ARV) treatment history or to replace the current ARV regimen in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable ARV regimen for ≥6 months with no history of treatment failure and no known resistance to any component of STRIBILD.


  • STRIBILD [package insert]. Foster City, CA: Gilead Sciences, Inc; 2014.
  • Cohen C, Post F, Winston J, et al. Week 144 renal safety of elvitegravir/ cobicistat/emtricitabine/tenofovir DF (STB) from two phase 3 randomized controlled trials. 20th International AIDS Conference; July 20-25, 2014; Melbourne, Australia. Abstract #WEPE063.
  • Clumeck N, Molina JM, Henry K, et al; GS-236-0103 Study Team. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr. 2014;65(3):e121-e124.

Please click here to view full Prescribing Information for STRIBILD, including BOXED WARNING

Important Safety Information

Dosage and administration

  • Adult dosage: One tablet taken orally once daily with food.
  • Renal impairment: Do not initiate in patients with CrCl below 70 mL/min. Discontinue in patients with CrCl below 50 mL/min.
  • Hepatic impairment: Not recommended in patients with severe hepatic impairment.
  • Testing prior to initiation: Test patients for HBV infection and document baseline CrCl, urine glucose, and urine protein.
Loading the player ...

By following this link, you are now leaving This site is not controlled by Gilead Sciences, Inc. Gilead Sciences, Inc. is not responsible for the site’s content or your use of the site.

Leave Site

Go Back